131 related articles for article (PubMed ID: 3165079)
1. [Immunohistochemical demonstration of CA 125, CA 19-9 and CEA in normal and pathologically changed adnexa].
Neunteufel W; Breitenecker G
Geburtshilfe Frauenheilkd; 1988 May; 48(5):334-7. PubMed ID: 3165079
[TBL] [Abstract][Full Text] [Related]
2. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
Neunteufel W; Breitenecker G
Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
[TBL] [Abstract][Full Text] [Related]
3. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
[TBL] [Abstract][Full Text] [Related]
4. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M
Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567
[TBL] [Abstract][Full Text] [Related]
5. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases.
Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K
Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
Oishi T; Maruo T; Iwasaki M; Mochizuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
[TBL] [Abstract][Full Text] [Related]
8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
9. [Tumor markers in gynecologic diseases].
Geyer H; Kleine W
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
11. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts.
Woo MM; Gilks CB; Verhage HG; Longacre TA; Leung PC; Auersperg N
Gynecol Oncol; 2004 May; 93(2):315-9. PubMed ID: 15099939
[TBL] [Abstract][Full Text] [Related]
12. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
14. Telomerase activity as a biological marker in some gynecological tumors: comparison with tissue and serum CA 125.
Novakovic S; Fras PA; Jezersek-Novakovic B
In Vivo; 2001; 15(4):327-32. PubMed ID: 11695225
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
Ryuko K; Iwanari O; Kitao M; Moriwaki S
Gynecol Oncol; 1993 May; 49(2):215-24. PubMed ID: 8504990
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
17. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies.
van Niekerk CC; Vooijs P; Casparie-van Velsen IJ; Poels LG
Cancer Detect Prev; 1997; 21(3):247-57. PubMed ID: 9167042
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
19. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types.
Rutgers JL; Bell DA
Mod Pathol; 1992 Jul; 5(4):367-71. PubMed ID: 1495942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
